Successful Type C Meeting with US FDA Regarding Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Announced
“We were very pleased that we made meaningful progress with the FDA on the potential of using immune activation biomarker data as a surrogate endpoint of clinical efficacy and on the proposed design of a confirmatory study design required to be initiated prior to received Accelerated Approval,” said Paul Romness, Chairman & CEO of OS Therapies. “Dr. Anderson’s meaningful contribution helped shape the conversation about the significant unmet medical need and inform the agency about the critical value of Comparative Oncology in potentially helping speed therapies to market in osteosarcoma. We expect not only to have biomarker data from our human clinical study to share with FDA, but also to have additional biomarker data from our canine program in frontline osteosarcoma which is the disease setting that FDA suggested may be suitable to conduct a confirmatory randomized study as part of an agreement with the agency regarding Accelerated Approval.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines